Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Zhang L, et al. Among authors: yun s. Hum Pathol. 2023 Jun;136:1-15. doi: 10.1016/j.humpath.2023.03.002. Epub 2023 Mar 22. Hum Pathol. 2023. PMID: 36958463 Review.
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Zhang Y, et al. Among authors: yun s. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):e150-e163. doi: 10.1016/j.clml.2022.12.008. Epub 2022 Dec 18. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36624015
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini M, Song J, Yun S, Talati C, Kuykendall A, Padron E, Walker A, Roboz G, Desai P, Sallman D, Sweet K, Komrokji R, Lancet J. Chan O, et al. Among authors: yun s. Blood Adv. 2024 Mar 12;8(5):1075-1083. doi: 10.1182/bloodadvances.2023011173. Blood Adv. 2024. PMID: 38170740 Free PMC article.
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Aguirre LE, et al. Among authors: yun s. Clin Lymphoma Myeloma Leuk. 2024 Jul;24(7):459-467. doi: 10.1016/j.clml.2024.03.001. Epub 2024 Mar 11. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38548563
Methodological Challenges in Randomized Controlled Trials of mHealth Interventions: Cross-Sectional Survey Study and Consensus-Based Recommendations.
Lopez-Alcalde J, Wieland LS, Yan Y, Barth J, Khami MR, Shivalli S, Lokker C, Rai HK, Macharia P, Yun S, Lang E, Bwanika Naggirinya A, Campos-Asensio C, Ahmadian L, Witt CM. Lopez-Alcalde J, et al. Among authors: yun s. J Med Internet Res. 2024 Dec 19;26:e53187. doi: 10.2196/53187. J Med Internet Res. 2024. PMID: 39700488 Free article.
4,421 results